logo
Lululemon has a lot of problems, say Jefferies analysts: 'Sesame Street' colors, way too many logos, and sales, sales, sales

Lululemon has a lot of problems, say Jefferies analysts: 'Sesame Street' colors, way too many logos, and sales, sales, sales

Lululemon is straying far from its yoga roots, and it could hurt the business, analysts say.
In a Wednesday note, Jefferies analysts identified several issues with the Vancouver-based athleisure brand's offerings. The analysts visited two Lululemon stores, one in Westport, Connecticut, and another in Coral Gables, Florida, to weed out product problems.
For one, the analysts said Lululemon was leaning too heavily into large logos to sell its products, and straying far from its yoga roots.
"LULU continues to stray further away from its yoga-inspired roots to designs similar to general apparel brands like the Gap," the note said.
They said Lululemon was trying to introduce new colors and products to solve its product struggles, but this resulted in a "disjointed assortment that's failing to convert."
Lululemon's comparable sales in the Americas in the first quarter of 2025, which ended on May 4, decreased 2% compared to the year before. Its stock is down more than 38% from the start of the year.
Chip Wilson, Lululemon's founder and the brand's former CEO, also said in a Forbes interview last January that the brand's offerings were becoming like the Gap.
"They're trying to become like the Gap, everything to everybody. And I think the definition of a brand is that you're not everything to everybody," Wilson said to Forbes.
The Jefferies note added that new designs at the two stores in Connecticut and Florida featured "loud colors and large logos in an attempt to sell beyond their core customer and attract younger shoppers."
"Color Palette Goes Sesame Street," the analysts said of Lululemon's new colors. The note came with pictures of bright purple, pink, yellow, and blue clothing items on store shelves.
They said the new products, instead of attracting new buyers, will alienate Lululemon's base consumers and quickly end up on sales racks.
This was another problem the analysts raised — the excessive number of items on sale in the two stores. They found seven and 11 sales racks in the Coral Gables store and the Westport outlet, respectively, and over 1,000 items on sale on the brand's website.
"It is becoming evident that the company is struggling with sell through and is resorting to markdowns to clear inventories," the analysts wrote in the note.
To be sure, some retailers try to clear stock in the summer to make way for new items for the back-to-school shopping rush.
And the long-awaited Align No Line leggings, which are Lululemon's bestseller yoga leggings without front seams, were out of stock in both the stores the analysts visited, the note said.
The Jefferies note comes shortly after Lululemon sued Costco for ripping off the designs of some of its bestsellers, like its Define jackets and ABC pants. In the 49-page filing on June 27, Lululemon said Costco had created "confusingly similar" dupes of its products.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Hidden Math That Makes Some Australians Poorer for Working Harder
The Hidden Math That Makes Some Australians Poorer for Working Harder

Epoch Times

time26 minutes ago

  • Epoch Times

The Hidden Math That Makes Some Australians Poorer for Working Harder

AD It may seem counterintuitive, but working longer hours can make you less money, the e61 Institute says. A pile of bills in Brisbane, Australia, on Oct. 30, 2013. AAP Image/Dan Peled 8/13/2025 | Updated: 8/13/2025 Not so long ago, working harder was thought to guarantee you were better off. Rex Widerstrom is a New Zealand-based reporter with over 40 years of experience in media, including radio and print. He is currently a presenter for Hutt Radio. Author's Selected Articles

Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market

Business Upturn

time29 minutes ago

  • Business Upturn

Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market

Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The product is the generic equivalent of Janssen Pharmaceuticals' blockbuster anticoagulant, Xarelto, and will be manufactured at Indoco's Verna, Goa facility. The approved Rivaroxaban tablets are bioequivalent and therapeutically equivalent to Xarelto and are indicated for the treatment of venous thromboembolism (VTE). This approval marks another milestone in Indoco's push into the US generics market, one of the most lucrative pharmaceutical markets globally. Commenting on the development, Indoco Remedies' Managing Director Aditi Panandikar said, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a global footprint, generating over 106 million prescriptions annually in India alone. The company operates 11 manufacturing facilities — seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs) — all of which are approved by top global regulatory agencies including the USFDA and UK-MHRA. With a turnover of $180 million and a workforce of more than 6,000 employees, Indoco is known for popular domestic brands such as Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Cital. Internationally, the company partners with large generics players to expand its market reach across multiple geographies. The latest USFDA approval strengthens Indoco's product portfolio in the regulated market and could open up significant revenue opportunities as Rivaroxaban continues to be a widely prescribed oral anticoagulant in the US. Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Investors should consult a qualified financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

Jefferies Sticks to Its Hold Rating for Celanese (CE)
Jefferies Sticks to Its Hold Rating for Celanese (CE)

Business Insider

time2 hours ago

  • Business Insider

Jefferies Sticks to Its Hold Rating for Celanese (CE)

Jefferies analyst Laurence Alexander maintained a Hold rating on Celanese today and set a price target of $47.00. The company's shares closed today at $41.22. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alexander covers the Basic Materials sector, focusing on stocks such as MP Materials, Ashland, and Ecolab. According to TipRanks, Alexander has an average return of -2.1% and a 45.55% success rate on recommended stocks. In addition to Jefferies, Celanese also received a Hold from BMO Capital's John McNulty in a report issued today. However, on the same day, Wells Fargo maintained a Buy rating on Celanese (NYSE: CE). CE market cap is currently $5.19B and has a P/E ratio of -3.20. Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CE in relation to earlier this year. Most recently, in May 2025, Mark Christopher Murray, the SVP – Acetyls of CE bought 1,479.00 shares for a total of $77,174.22.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store